STATEMENT: AllCells expands the apheresis network for the demand for cell and gene therapy products and services

(Information sent by the signatory company).

STATEMENT: AllCells expands the apheresis network for the demand for cell and gene therapy products and services

(Information sent by the signatory company)

-AllCells expands apheresis network to meet rapidly growing demand for cell and gene therapy products and services

ALAMEDA, Calif., Feb. 22, 2023 /PRNewswire/ -- AllCells®, a Discovery Life Sciences™ company and leading provider of critical cell and gene therapy (CGT) starting materials and services, has announced the expansion of its network of apheresis with the addition of two new centers in Houston, Texas, and Huntsville, Alabama. These new centers complement AllCells' current presence in two major US biotech hubs - the San Francisco Bay and Boston metropolitan areas - further consolidating its market leadership position and bolstering its ability to meet growing demand. worldwide of CGT products and services.

AllCells is a recognized world leader in service and quality thanks to its 99% delivery rate and adherence to rigorous quality standards. With more than 3,700 CGT-focused clinical trials underway around the world, the company has invested significant resources to expand collection sites and increase its apheresis capacity to meet the appropriate requirements for each phase.

In addition to the expansion of its facilities, AllCells has expanded its donor digital marketing, specialist recruitment and event organization efforts, and has also expanded its highly experienced project management team to support new and ongoing GMP projects. As a result, clients have access to tens of thousands of well-characterized, highly compromised, and recoverable donors, along with in-house access to comprehensive analytical characterization, including cell biology, genomics, and proteomic capabilities.

"This expansion is a key milestone for AllCells in our mission to become the world's most trusted provider of CGT solutions," said Danny Zheng, President of AllCells. "Our continued investments allow us to offer our customers a highly characterized supply chain through a single, robust and scaled resource as they pursue significant advances in the field of CGT."

About AllCells

Founded in 1998, AllCells, a Discovery Life Sciences company, is a market-leading provider of highly characterized primary cellular and tissue products, supporting global biomedical organizations seeking to develop and manufacture new drugs and cellular therapies. By providing RUO and clinical grade products, personalized donor management services and integrated analytical capabilities, AllCells end-to-end solutions streamline each stage of development to help bring new therapies to market faster. Our FDA-registered, IRB-approved, and AABB-compliant donor facilities strategically located throughout the US provide access to healthy, recoverable, and well-characterized donors with diverse and rare demographics. Our adjacent processing facilities allow for immediate processing, cryopreservation, and a high degree of responsiveness to meet custom requests with exceptional quality and deliverability. Backed by more than 30 years of combined science and regulatory experience, AllCells is committed to providing flexible and scalable solutions needed for specific, dynamic customer needs and timelines from inception to market. AllCells – Science at your Service™

Logo -

View original content: